CAMBRIDGE, Mass.--(BUSINESS WIRE)--Good Start Genetics®, Inc., a family genetics information solutions company, announced today that it has appointed seasoned life sciences industry executive, Jeffrey Luber, to the post of president and chief executive officer (CEO). Luber has also been appointed to the Good Start Genetics Board of Directors.
“I’m extremely proud of the talented team of professionals at Good Start Genetics who have developed best-in-class products, processed more than one million tests since the company’s inception and created a brand synonymous with quality and better family health,” said Luber. “I look forward to working closely with the team to leverage our strong foundation and propel our future in existing and new markets.”
For two decades, Luber has been a life sciences executive in both public and private companies. Prior to his appointment as CEO, Luber served as Good Start Genetics’ general counsel and head of corporate development, where he established a number of key relationships and new business models central to the company’s growth in expanding markets. Previously, Luber co-founded SynapDx, developer of blood-based technologies for the early detection of autism. Luber also held several executive positions at EXACT Sciences Corporation (NASDAQ: EXAS) including, president in 2007 and president and CEO from 2008-2009.
“Jeff’s business acumen, commitment to innovation and breadth of vision are critical to leading Good Start Genetics through its next phase of growth,” said Marc Beer, board chairman of Good Start Genetics. “Our company is evolving quickly, growing in existing franchises as well as new markets for the family. In addition, we are expanding in new ways through patient-directed offerings, for which Jeff’s talents, accomplishments and unique perspectives are particularly well-suited.”
“With the pace of genomic discovery increasing rapidly and families in need of timely, reliable and consistent solutions for better reproductive health, we are pleased to support Jeff in leading the company through the next phase of growth,” said Carl Gordon, founding partner and co-head of global private equity at OrbiMed. “Good Start Genetics continues to expand its footprint in exciting new markets through its steady launch of cutting edge products in clinical sequencing, strong and innovative partnerships and market-leading positioning. Jeff’s insights, leadership and experience will continue to drive the company in providing information solutions to a variety of stakeholders, both domestically and abroad.”
About Good Start Genetics®, Inc.
Good Start Genetics is an
information solutions company delivering best-in-class genetics
offerings to growing families. Using advanced clinical sequencing,
proprietary methods and information tailored to the individual, the
Company’s suite of offerings arm clinicians and patients with insightful
and actionable information to promote successful pregnancies and help
build healthy families. Its flagship genetic carrier screening service, GeneVu™,
is a comprehensive menu of highly-accurate tests for known and novel
mutations that cause inherited genetic disorders, and its proprietary
and advanced preimplantation genetic screening test, EmbryVu™,
based on technologies exclusively licensed from Johns Hopkins
University, is helping a wider range of couples find their paths to
pregnancy at significantly lower costs. Good Start Genetics complements
these offerings with world-class customer care and genetic counseling to
help families stay well-informed and best prepare for tomorrow. For more
information, please visit www.goodstartgenetics.com
or join us on Facebook,
Twitter
and LinkedIn.
